{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:13:51Z","timestamp":1790792031460,"version":"4.1.0"},"reference-count":42,"publisher":"Japanese Society of Internal Medicine","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026,1,15]]},"DOI":"10.2169\/internalmedicine.5157-24","type":"journal-article","created":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T17:12:40Z","timestamp":1741367560000},"page":"245-251","source":"Crossref","is-referenced-by-count":1,"title":["Development of Antiviral Drugs for Influenza"],"prefix":"10.2169","volume":"65","author":[{"given":"Tadashi","family":"Ishida","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, Ohara Memorial Kurashiki Medical Foundation, Kurashiki Central Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. National institute of infectious diseases. Infectious agents surveillance report. 40: 177-200, 2019 (in Japanese)."},{"key":"2","unstructured":"2. National institute of infectious diseases. Weekly reports of detection of influenza virus. 2024.9.20 (in Japanese)."},{"key":"3","unstructured":"3. Australian government Department of health and age care. Australian respiratory surveillance report 2024, No.13."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Uyeki TM, Bernstein HH, Bladley JS, et al. Clinical practice guidelines by the Infectious Diseases Society of America: 2018 update on diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenza. Clin Infect Dis 68: 895-902, 2019.","DOI":"10.1093\/cid\/ciy874"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Ishida T, Seki M, Oishi K, et al. Clinical manifestations of hospitalized influenza patients without risk factors: a prospective multicenter cohort study in Japan<i> via<\/i> internet surveillance. J Infect Chemother 23: 853-858, 2022.","DOI":"10.1016\/j.jiac.2022.02.001"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Yu H, Liao Q, Yuan Y, et al. Effectiveness of oseltamivir on disease progression and viral RNA shedding in patients with mild pandemic 2009 influenza A H1N1: opportunistic retrospective study of medical charts in China. BMJ 341: c4779, 2010.","DOI":"10.1136\/bmj.c4779"},{"key":"7","unstructured":"7. Rodriguez A, Diaz E, Martin-Loches I, et al. Impact of early oseltamivir treatment on outcome in critically ill patients with 2009 pandemic influenza A. J Antimicrob Chemother 66: 1140-1149, 2011."},{"key":"8","unstructured":"8. Muthuri SG, Venkatesan S, Myles PR, et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. Lancet Respir Med 2: 395-404, 2014."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Jefferson T, Jones MA, Doshi P, Elizabeth AS, Igho O, Carl JH. Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ 348: g2545, 2014.","DOI":"10.1136\/bmj.g2545"},{"key":"10","doi-asserted-by":"publisher","unstructured":"10. Dobson J, Whitley RJ, Pocock S, Monto AS. Oseltamivir treatment for influenza in adults: a meta-analysis of randomized controlled trials. Lancet 385: 1729-1737, 2015.","DOI":"10.1016\/S0140-6736(14)62449-1"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Venkatesan S, Myles PR, Leonardi-Bee J, et al. Impact of outpatient neuraminidase inhibitor treatment in patients infected with influenza A (H1N1) pdm09 at high risk of hospitalization: an individual participant data meta-analysis. Clin Infect Dis 64: 1328-1334, 2017.","DOI":"10.1093\/cid\/cix127"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Doll MK, Winters N, Boikos C, Kraicer-Melamed H, Gore G, Quach C. Safety and effectiveness of neuraminidase inhibitors for influenza treatment, prophylaxis, and outbreak control: a systematic review of systematic reviews and\/or meta-analyses. J Antimicrob Chemother 72: 2990-3007, 2017.","DOI":"10.1093\/jac\/dkx271"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Writing Committee of the WHO Consultation on Clinical Aspects of Pandemic (H1N1) 2009 Influenza. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med 362: 1708-1719, 2010.","DOI":"10.1056\/NEJMra1000449"},{"key":"14","unstructured":"14. Centers for Disease Control and Prevention. Influenza antiviral medications: summary for clinician [Internet]. 2023 Dec 8 [cited 2024 Dec 1]. Available from: https:\/\/www.cdc.gov\/flu\/hcp\/antivirals\/summary-clinicians.html"},{"key":"15","unstructured":"15. National institute of infectious diseases. Infectious agents surveillance report. 31: 250-251, 2010 (in Japanese)."},{"key":"16","unstructured":"16. The Influenza Committee of the Japanese Association for Infectious Diseases The statement: about anti-influenza medications. 2019.10.19 [Internet]. [cited 2024 Dec 1]. Available from: http:\/\/www.kansensho.or.jp\/uploads\/files\/guidelines\/191024_teigen.pdf"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. M\u00e4kel\u00e4 MJ, Pauksens K, Rostila T, et al. Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: a randomized, double-blind, placebo-controlled European study. J Infect 40: 42-48, 2000.","DOI":"10.1053\/jinf.1999.0602"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Hedrick JA, Barzilai A, Behre U, et al. Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: a randomized controlled trial. Pediatr Infect Dis J 19: 410-417, 2000.","DOI":"10.1097\/00006454-200005000-00005"},{"key":"19","doi-asserted-by":"publisher","unstructured":"19. Hu Y, Lu S, Song Z, et al. Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance. Lancet 381: 2273-2279, 2013.","DOI":"10.1016\/S0140-6736(13)61125-3"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Sugaya N, Mitamura K, Yamazaki M, et al. Lower clinical effectiveness of oseltamivir against influenza B contrasted with influenza A infection in children. Clin Infect Dis 44: 197-202, 2007.","DOI":"10.1086\/509925"},{"key":"21","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1001\/jama.297.13.1435","volume":"297","author":"S Hatakeyama","year":"2007","unstructured":"21. Hatakeyama S, Sugaya N, Ito M, et al. Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors. JAMA 297: 1435-1442, 2007.","journal-title":"JAMA The Journal of the American Medical Association","ISSN":"https:\/\/id.crossref.org\/issn\/0098-7484","issn-type":"print"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Sugaya N, Tamura D, Yamazaki M, et al. Comparison of the clinical effectiveness of oseltamivir and zanamivir against influenza virus infection in children. Clin Infect Dis 47: 339-345, 2008.","DOI":"10.1086\/589748"},{"key":"23","unstructured":"23. National Institute of Infectious Diseases. Anti-influenza drug-resistant strains surveillance report. (in Japanese) 2024 Sep 13 [Internet]. [cited 2024 Dec 1]. Available from: https:\/\/www.niid.go.jp\/niid\/ja\/influ-resist.html"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Kohno S, Yen MY, Cheong HJ, et al. Phase III randomized, double-blind study comparing single-dose intravenous peramivir with oral oseltamivir in patients with seasonal influenza virus infection. Antimicrob Agents Chemother 55: 5267-5276, 2011.","DOI":"10.1128\/AAC.00360-11"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Kohno S, Yen MY, Cheong HJ, et al. Phase III randomized, double-blind study comparing single-dose intravenous peramivir with oral oseltamivir in patients with seasonal influenza virus infection. Antimicrob Agents Chemother 55: 5267-5276, 2011.","DOI":"10.1128\/AAC.00360-11"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. de Jong MD, Ison MG, Monto AS, et al. Evaluation of intravenous peramivir for treatment of influenza in hospitalized patients. Clin Infect Dis 59: e172-e185, 2014.","DOI":"10.1093\/cid\/ciu632"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Sugaya N, Kohno S, Ishibashi T, Wajima T, Takahashi T. Efficacy, safety, and pharmacokinetics of intravenous peramivir in children with 2009 pandemic H1N1 influenza A virus infection. Antimicrob Agents Chemother 56: 369-377, 2012.","DOI":"10.1128\/AAC.00132-11"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Watanabe A, Chang SC, Kim MJ, Chu DW, Ohashi Y; MARVEL Study Group. Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: a double-blind, randomized, non-inferiority clinical trial. Clin Infect Dis 51: 1167-1175, 2010.","DOI":"10.1086\/656802"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Sugaya N, Ohashi Y. Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection. Antimicrob Agents Chemother 54: 2575-2782, 2010.","DOI":"10.1128\/AAC.01755-09"},{"key":"#cr-split#-30.1","unstructured":"30. Ikematsu H, Kawai N, Iwaki N, et al. Duration of fever and other symptoms after the inhalation of laninamivir octanoate hydrate in the 2016\/17 Japanese influenza season"},{"key":"#cr-split#-30.2","doi-asserted-by":"crossref","unstructured":"comparison with the 2011\/12 to 2015\/16 seasons. J Infect Chemother 24: 718-724, 2018.","DOI":"10.1016\/j.jiac.2018.04.013"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Hayden FG, Sugaya N, Hirotsu N, et al. Baloxavir marboxil for uncomplicated influenza in adults and adolescents. N Engl J Med 379: 913-923, 2018.","DOI":"10.1056\/NEJMoa1716197"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Ison MG, Portmouth S, Yoshida Y, et al. Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial. Lancet Infect Dis 20: 1204-1214, 2020.","DOI":"10.1016\/S1473-3099(20)30004-9"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Uehara T, Hayden FG, Kawaguchi K, et al. Treatment -emergent influenza variant viruses with reduced baloxavir susceptibility: impact on clinical and virologic outcomes in uncomplicated influenza. J Infect Dis 221: 346-355, 2019.","DOI":"10.1093\/infdis\/jiz244"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Nakazawa M, Hara K, Komeda T, Ogura E. Safety and effectiveness of baloxavir marboxil for the treatment of influenza in Japanese clinical practice: a post marketing surveillance of more than 3000 patients. J Infect Chemother 26: 729-735, 2020.","DOI":"10.1016\/j.jiac.2020.04.014"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Kuo Y, Lai CC, Wang YH, Chen CH, Wang CY. Clinical efficacy and safety of baloxavir marboxil in the treatment of influenza: a systematic review and meta-analysis of randomized controlled trials. J Microbiol Immunol Infect 54: 856-875, 2021.","DOI":"10.1016\/j.jmii.2021.04.002"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Shiraishi C, Kato H, Hagihara M, Asai N, Iwamoto T, Mikamo H. Comparison of clinical efficacy and safety of baloxavir marboxil versus oseltamivir as the treatment for influenza virus infections: A systematic review and meta-analysis. J Infect Chemother 30: 242-249, 2024.","DOI":"10.1016\/j.jiac.2023.10.017"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Baker J, Block SL, Matharu B, et al. Baloxavir marboxil single-dose treatment in influenza-infected children. a randomized, double blind, active controlled phase 3 safety and efficacy trial (miniSTONE-2). Pediatr Infect Dis J 39: 700-705, 2020.","DOI":"10.1097\/INF.0000000000002747"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Sato M, Takashita E, Katayose M, et al. Detection of variants with reduced baloxavir marboxil susceptibility after treatment of children with influenza A during the 2018-2019 influenza season. J Infect Dis 222: 121-125, 2020.","DOI":"10.1093\/infdis\/jiaa061"},{"key":"39","unstructured":"39. The Influenza Committee of the Japanese Association for Infectious Diseases New statement about cap-dependent endonuclease inhibitor, baloxavir marboxil. (in Japanese) 2023 Nov 27 [Internet]. [cited 2024 Dec 1]. Available from: https:\/\/www.kansensho.or.jp\/uploads\/files\/guidelines\/teigen_231130_nashi.pdf"},{"key":"40","unstructured":"40. The Japan Pediatric Society: The guidance of treatment and prevention for 2024\/25 season influenza. (in Japanese) 2024 Oct 27 [Internet]. Available from: https:\/\/www.jpeds.or.jp\/uploads\/files\/20241028_2024-2025_infuru_shishin.pdf"},{"key":"41","unstructured":"41. The Japanese Association for Infectious Diseases and the Japanese Society of Chemotherapy: The guidelines for infectious diseases 2023. (in Japanese)."}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/2\/65_5157-24\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T03:32:15Z","timestamp":1768620735000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/2\/65_5157-24\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,15]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.5157-24","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,15]]},"article-number":"5157-24"}}